Accent data presented at 2026 ASCO Gastrointestinal Cancer Symposium

Highlights

• Results from the Phase 2a ACCENT trial in pancreatic cancer have been presented at the specialist conference ASCO Gastrointestinal Cancer Symposium
• Updated data analysis continues to show that Narmafotinib combination compares favourably with gemcitabine and Abraxane combination alone.